FMP
Interpace Biosciences, Inc.
IDXG
PNK
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
0.89 USD
-0.03 (-3.37%)
2023
2022
2021
2020
40.21M
31.84M
41.31M
32.4M
16.31M
13.61M
23.37M
21.67M
23.9M
18.23M
17.95M
10.72M
21.1M
22.07M
29.68M
37.28M
636k
703k
1.88M
2.79M
19.6M
20.1M
23.74M
30.02M
10.23M
9.13M
10.07M
9.25M
9.36M
10.97M
13.67M
20.77M
868k
1.27M
4.06M
4.46M
2.8M
-3.84M
-11.74M
-26.55M
-1.68M
-2.22M
-1.41M
-82k
1.13M
-5.84M
-15.41M
-26.15M
17k
29k
-667k
53k
802k
-5.87M
-14.75M
-26.2M
0.19
-1.38
-3.57
-6.5
0.18
-1.38
-3.57
-6.5
4.32M
4.24M
4.13M
4.03M
4.36M
4.24M
4.13M
4.03M
3.84M
-2.27M
-1.33M
-20.1M
All figures are in USD.